Journal profile · Peripheral Vascular Disease
Current Vascular Pharmacology
ISSN 1570-1611 · eISSN 1875-6212 · Bentham Science Publishers B.V. · ENGLAND · Quarterly · Founded 2003
Current Vascular Pharmacology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.34; hybrid open access; median 133 days to acceptance (75 articles, last 24 months); community-reported acceptance: fairly easy; 52 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Vascular Pharmacology is published by Bentham Science Publishers B.V. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lipoproteins and Cardiovascular Health, Antiplatelet Therapy and Cardiovascular Diseases and Diabetes, Cardiovascular Risks, and Lipoproteins, together about 21.8% of its articles. Its main subfields are Cardiology and Cardiovascular Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Current Vascular Pharmacology publishes clinical and research-based reviews/mini-reviews, original research articles, letters, debates, drug clinical trial studies and guest edited issues to update all those concerned with the treatment of vascular disease, bridging the gap between clinical practice and ongoing research. Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units).
Source: LetPub
Research area (LetPub): Peripheral Vascular Disease
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lipoproteins and Cardiovascular HealthMedicine9.8%
- Antiplatelet Therapy and Cardiovascular DiseasesMedicine6.5%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine5.5%
- Blood Pressure and Hypertension StudiesMedicine5.2%
- Cancer, Lipids, and MetabolismBiochemistry, Genetics and Molecular Biology4.9%
- Peripheral Artery Disease ManagementMedicine4.4%
- Atrial Fibrillation Management and OutcomesMedicine4.2%
- Nitric Oxide and Endothelin EffectsMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Peripheral Vascular Disease | Zone 4 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Peripheral Vascular Disease | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Peripheral Vascular Disease | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.34LetPub ·
- CiteScore 2026-06
- 3.6LetPub ·
- SJR 2026-06
- 0.6LetPub ·
- SNIP 2026-06
- 0.54LetPub ·
- h-index
- 54LetPub ·
- h-index
- 81OpenAlex ·
- i10-index
- 900OpenAlex ·
- 2-year mean citedness
- 2.33OpenAlex ·
- Self-citation rate
- 8.3%LetPub ·
- Share of gold OA articles
- 6.56%LetPub ·
Volume
- Articles per year
- 43LetPub ·
Articles by year OpenAlex count · 1,672 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 28 | 1 | 1 |
| 2025 | 52 | 4 | 102 |
| 2024 | 40 | 4 | 177 |
| 2023 | 64 | 4 | 313 |
| 2022 | 44 | 6 | 225 |
| 2021 | 51 | 3 | 593 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
133 daysMedian, submission to acceptance · P25–P75 72 days – 178 days
- Acceptance to online
- median 171 days (75 articles)
- Submission to online
- median 314 days
- Sample
- 75 articles with submission and acceptance dates (103 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham Science Publishers B.V.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Quarterly
- Founded
- 2003
- ISSN
- 1570-1611
- Electronic ISSN
- 1875-6212
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Current Vascular Pharmacology
What CAS zone is Current Vascular Pharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Vascular Pharmacology is in Zone 4 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy / Peripheral Vascular Disease. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Vascular Pharmacology?
The latest impact factor listed by LetPub is 2.34; CiteScore 3.6, h-index 81.
How long does peer review take at Current Vascular Pharmacology?
Based on the dates recorded on 75 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 133 days (interquartile range 72–178 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Current Vascular Pharmacology?
According to LetPub and DOAJ records, Current Vascular Pharmacology is indexed in SCIE and Scopus.
Is Current Vascular Pharmacology open access, and what is the APC?
Current Vascular Pharmacology is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .